Routine Use of the Direct Thrombin Inhibitor Bivalirudin for Off-Pump Coronary Artery Bypass Grafting is Safe and Effective


  • George J. Palmer
  • Iyer S. Sankaran
  • Gary M. Sparkman
  • Andreas Koster
  • Cornelius M. Dyke
  • George Ebra



Anticoagulation with unfractionated heparin has been the standard of care for more than a half-century for patients undergoing cardiac surgery. The risk of heparin-induced adverse reactions dictates the need for a safe and effective alternative, particularly in off-pump coronary artery bypass (OPCAB) surgery, an approach associated with a perioperative prothrombotic condition that may negatively influence graft patency. Between March 2003 and January 2005, 243 consecutive patients underwent OPCAB with bivalirudin (0.75 mg/kg bolus with 1.75 mg/kg per hour infusion). There were 171 men (70.4%) and 72 women (29.6%). The mean age was 64.9 ± 10.9 years (age range 32-88 years). There were 147 patients (60.5%) with 3-vessel disease; 46 (18.9%) had substantial (>50%) stenosis of the left main coronary artery; 104 (42.8%) had a moderately reduced (0.30 to 0.50) ejection fraction; and 9 (3.7%) had a severely reduced (<0.30%) ejection fraction. Five patients (2.1%) required conversion to cardiopulmonary bypass and subsequently received heparin. Postoperative complications included perioperative myocardial infarction in 6 patients (2.5%), stroke in 3 (1.2%), prolonged ventilation in 4 (1.6%), reoperation for bleeding in 3 (1.2%), renal insufficiency in 14 (5.8%), atrial fibrillation in 26 (10.7%), low cardiac output in 3 (1.2%), and deep sternal infection in 1 (0.4%). Blood products were used in 117 patients (48.1%). The overall hospital mortality rate was 0.4% (1 of 243). Bivalirudin is a safe and effective anticoagulant that may be routinely used as an alternative to heparin and protamine in patients undergoing OPCAB. This is evidenced by low hospital mortality and morbidity rates. Further follow-up is warranted to discern the influence of bivalirudin on long-term clinical outcomes.


Angelini GD, Taylor FC, Reeves BC, Ascione R. 2002. Early and midterm outcome after off-pump and on-pump surgery in Beating Heart Against Cardioplegic Arrest Studies (BHACAS 1 and 2): a pooled analysis of two randomized controlled trials. Lancet 359:1194-9.nBartholomew JR, Begelman SM, Almahameed A. 2005. Heparin-induced thrombocytopenia: principles for early recognition and management. Cleve Clin J Med 72(suppl 1):S31-6.nBates SM, Weitz JI. The mechanism of action of direct thrombin inhibitors. 2000. J Invasive Cardiol 12:27-32.nBennett-Guerrero E, Slaughter TF, White WD, et al. 2005. Preoperative anti-PF4/H antibody level predicts adverse outcome after cardiac surgery. J Thorac Cardiovasc Surg 130:1567-72.nBott JN, Reddy K, Krick S. 2003. Bivalirudin use in off-pump myocardial revascularization in patients with heparin-induced thrombocytopenia. Ann Thorac Surg 76:273-5.nCohn LH. Fifty years of open-heart surgery. 2003. Circulation 107:2168-70.nD'Ancona G, Donias HW, Karamanoukian RL, Bergsland J, Karamanoukian HL. 2001. OPCAB therapy survey: off-pump clopidogrel, aspirin or both therapy survey. Heart Surg Forum 4:354-8.nDyke CM, Smedira NG, Koster A, et al. 2006. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: The EVOLUTION-ON study. J Thorac Cardiovasc Surg 131:533-9.nEdmunds LH Jr. 1995. Why cardiopulmonary bypass makes patients sick: strategies to control the blood-synthetic surface interface. Adv Card Surg 6:131-67.nFrancis JL, Palmer GJ, Moroose R, Drexler A. 2003. Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery. Ann Thorac Surg 75:17-22.nKhan NE, DeSouza A, Mister R, et al. 2004. A randomized comparison of off-pump and on-pump multi-vessel coronary artery bypass surgery. N Engl J Med 350:21-8.nKirklin J, Westaby S, Blackstone, et al. 1983. Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 86:845-57.nKoster A, Spiess B, Chew DP, et al. 2004. Effectiveness of bivalirudin as a replacement for heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting. Am J Cardiol 93:356-9.nLincoff AM, Bittl JA, Harrington RA, et al. 2003. Bivalirudin and provision glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 289:853-63.nMatar F, Donoghue C, Rossi P. 2006. Angiographic and clinical outcomes of bivalirudin versus heparin in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Can J Cardiol 22(13):1139-45.nMerry AF, Raudkivi PJ, Middleton NG, et al. 2004. Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery. Ann Thorac Surg 77:925-31.nPuskas JD, Williams WH, Duke PG, et al. 2003. Off-pump coronary artery bypass grafting provides complete revascularization with reduced myocardial injury, transfusion requirements and length of stay: a prospective randomized comparison of two hundred unselected patients undergoing off-pump versus conventional coronary artery bypass grafting. J Thorac Cardiovasc Surg 125:797-808.nRanucci M, Frigiola A, Menicanti L, Cazzaniga A, Soro G, Isgro G. 2001. Risk factors for fatal myocardial infarction after coronary bypass surgery. Eur J Anaesthesiol 18:322-9.nSedrakyan A, Wu AW, Parashar A, Bass EB, Treasure T. 2006. Off-pump surgery is associated with reduced occurrence of stroke and other morbidity as compared with traditional coronary artery bypass grafting: a meta-analysis of systematically reviewed trials. Stroke 37: 2759-69.nSmedira NG, Dyke CM, Koster A, et al. 2006. Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: The results of the EVOLUTION-OFF study. J Thorac Cardiovasc Surg 131:686-92.nVan Dijk D, Nierich AP, Jansen EWL, et al. 2001. Early outcome after off-pump versus on-pump coronary bypass surgery: results from a randomized study. Circulation 104:1761-6.nWarkentin TE, Greinacher A. 2003. Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg 76:2121-31.nWarkentin TE, Kelton JG. 2001. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 135:502-6.nWarkentin TE, Koster A. 2005. Bivalirudin: a review. Expert Opin Pharmacother 6:1349-71.nWilliams RT, Damaraju LV, Mascelli MA, et al. 2003. Anti-platelet factor 4/heparin antibodies: an independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes. Circulation 107:2307-12.n



How to Cite

Palmer, G. J., Sankaran, I. S., Sparkman, G. M., Koster, A., Dyke, C. M., & Ebra, G. (2008). Routine Use of the Direct Thrombin Inhibitor Bivalirudin for Off-Pump Coronary Artery Bypass Grafting is Safe and Effective. The Heart Surgery Forum, 11(1), E24-E29.




Most read articles by the same author(s)